Creatinine level and lipid profile of virally-suppressed adolescent and young adult living with HIV who use lamivudine and dolutegravir regimen HIV, pediatrics, adolescents, anti-retroviral drugs, dolutegravir, lamivudine
Conditions
Interventions
Participant HIV regimen will be changed to Lamivudine plus Dolutegravir regimen
1 tablet of 300 mg lamivudine and 1 tablet of 50 mg dolutegravir once a day, at least 1 year from the study initiation
Experimental Drug
Lamivudine plus Dolutegravir
Sponsors
Faculty of Medicine, Chulalongkorn University
Center of Excellence for Pediatric Infectious Diseases and Vaccines, Faculty of Medicine, Chulalongkorn University
Eligibility
Sex/Gender
All
Age
13 Years to 24 Years
Inclusion criteria
Inclusion criteria: 1. Age 13-24 year old 2. Tenofovir disoproxil+lamivudine +dolutegravir user 2. Bodyweight more than or equal to 35 Kg 3. HIV viral load less than 50 copies/mL within 6 months 4. CD4 more than 200 cells/mm3 within 6 months 5. Known their HIV status
Exclusion criteria
Exclusion criteria: 1. Chronic HBV infection 2.Creatinine clearance less than 30 mL/min/1.73 m2 3. Hepatic impairment (Child-Pugh C)4. History of dolutegravir resistant
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Renal function 3, 6, and 12 months after drug changing Creatinine level | — |
Secondary
| Measure | Time frame |
|---|---|
| Lipid status 3, 6, and 12 months after drug changing Total cholesterol, triglyceride, LDL and HDL level,Viral suppression 12 months after drug changing HIV viral load,User viewpoints throughout 2 drugs regimen 6 months after drug changing Patient reported viewpoints using a questionnaire | — |
Countries
Thailand
Contacts
Public ContactNapat Soonthornchat
Faculty of Medicine, Chulalongkorn University
Outcome results
None listed